Patents Assigned to Qiagen Sciences, LLC
  • Patent number: 11819851
    Abstract: A microfluidic device with a microfluidic circuit including an array of fluidly coupled microchambers. Each microchamber includes a reaction chamber and an associated vent chamber. The microfluidic circuit may be arranged so that a fluid sample introduced to microfluidic device flows into the reaction chamber and air or other gas present in the reaction chamber is vented from the microchamber through the vent chamber. The microchamber may be configured to allow only the flow of air into the vent chamber from the reaction chamber until the air has been displaced from the reaction chamber by the fluid sample and/or a predefined volume of the fluid sample has been received in the reaction chamber. The microchamber may be further configured to release the fluid sample to thereafter flow from the reaction chamber into the vent chamber.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: November 21, 2023
    Assignee: QIAGEN SCIENCES, LLC
    Inventors: Kabir James Yamana, Sean Yamana-Hayes
  • Patent number: 11814618
    Abstract: Provided are methods for isolating biomolecules, such as nucleic acids and proteins, from a sample using a silica-containing surface and/or a high salt, low pH buffer.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: November 14, 2023
    Assignee: QIAGEN Sciences, LLC
    Inventors: Heather Callahan, Eddie Adams, Mark N. Brolaski, Victoria Nieciecki
  • Patent number: 11725203
    Abstract: Provided are methods and compositions for negatively and positively selecting for different size nucleic acid (e.g., DNA or RNA) fragments on borosilicate glass fiber membranes, silica and metal oxide surfaces such that only those fragments falling within a desired size range are obtained.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: August 15, 2023
    Assignee: QIAGEN Sciences, LLC
    Inventors: Vince Moroney, Eddie Adams, Mark Brolaski, Ingemar Pedron
  • Patent number: 11401548
    Abstract: The present disclosure provides primers, primer sets, kits and methods for multiple displacement amplification, especially in combination with nucleic acid sequencing. The primers comprise self-complementary sequences at their 5? termini and random or semi-random sequences at their 3? termini. Use of such primers facilitates handling of multiple samples, increases sequence coverage uniformity, and improves sequencing error corrections.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: August 2, 2022
    Assignee: QIAGEN Sciences, LLC
    Inventors: Yexun Wang, Quan Peng
  • Patent number: 11371092
    Abstract: An imaging system for exciting and measuring fluorescence on or in samples comprising fluorescent materials (e.g. fluorescent labels, dyes or pigments). In one embodiment, a device is used to detect fluorescent labels on nucleic acid. In a preferred embodiment, the device is configured such that fluorescent labels in a plurality of different DNA templates are simultaneously detected.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: June 28, 2022
    Assignee: QIAGEN SCIENCES, LLC
    Inventors: Steven Gordon, Steven Auger, Alan Schinazi
  • Patent number: 11359237
    Abstract: Modular flow cells, devices with modular flow cells, and methods of sequencing using modular flow cells, as well as systems and kits including modular flow cells, are described, permitting sequencing wherein less than the full capacity for sequencing is desired.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: June 14, 2022
    Assignees: QIAGEN SCIENCES, LLC, QIAGEN GmbH
    Inventors: Jerzy Olejnik, Dirk Zimmermann
  • Patent number: 11353464
    Abstract: The present disclosure relates to methods for predicting time-to-delivery in pregnant women. The methods include predicting that a pregnant woman will deliver within a predetermined time frame if PAMG-1 is determined to be present at a level above a predetermined detection threshold in a vaginal fluid sample obtained from the pregnant woman. Also provided are methods for determining a patient's risk of preterm labor and/or spontaneous rupture of the chorioamniotic membrane.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: June 7, 2022
    Assignee: Qiagen Sciences, LLC
    Inventors: Anthony Ausiello, Ruben Salinas, Michael Thompson, Daniel J. Mackey, Kaitlyn Nardozzi, Michael Friedman
  • Patent number: 11155813
    Abstract: The present disclosure provides oligonucleotides that comprise semi-random barcode sequences. Such oligonucleotides may be incorporated into reverse transcription primers, PCR primers, or portions of sequencing adapters in preparing sequencing libraries. The resulting sequencing libraries can be used for accurate sequencing, including DNA or RNA counting and mutation detection. Methods and kits for preparing sequencing adapters and sequencing libraries are also provided.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: October 26, 2021
    Assignee: QIAGEN Sciences, LLC
    Inventors: Yexun Wang, Zhong Wu
  • Patent number: 11154864
    Abstract: A microfluidic device with a microfluidic circuit including an array of fluidly coupled microchambers. Each microchamber includes a reaction chamber and an associated vent chamber. The microfluidic circuit may be arranged so that a fluid sample introduced to microfluidic device flows into the reaction chamber and air or other gas present in the reaction chamber is vented from the microchamber through the vent chamber. The microchamber may be configured to allow only the flow of air into the vent chamber from the reaction chamber until the air has been displaced from the reaction chamber by the fluid sample and/or a predefined volume of the fluid sample has been received in the reaction chamber. The microchamber may be further configured to release the fluid sample to thereafter flow from the reaction chamber into the vent chamber.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: October 26, 2021
    Assignee: QIAGEN SCIENCES, LLC
    Inventors: Kabir James Yamana, Sean Yamana-Hayes
  • Patent number: 11046726
    Abstract: The present invention provides methods, compositions, mixtures and kits utilizing deoxynucleoside triphosphates comprising a 3?-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: June 29, 2021
    Assignee: QIAGEN SCIENCES, LLC
    Inventors: Mong Sano Marma, Jerzy Olejnik, Ilia Korboukh
  • Patent number: 11035823
    Abstract: The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. A plurality of smaller flow cells is employed, each with a relatively small area to be imaged, in order to provide greater flexibility and efficiency.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: June 15, 2021
    Assignee: Qiagen Sciences, LLC
    Inventors: Steven Gordon, Thomas Hagerott, Edmund Golaski, Jerzy Olejnik
  • Patent number: 11001887
    Abstract: The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: May 11, 2021
    Assignee: QIAGEN SCIENCES, LLC
    Inventors: Steven Gordon, Jerzy Olejnik
  • Patent number: 10983121
    Abstract: Compositions and methods are provided for detection, diagnosis and prognosis of Lyme disease (LD), including a method for confirming Borrelia spp. infection by contacting, in vitro, whole blood samples from subjects suspected of having LD with synthetic peptides comprising T-cell epitope-containing regions derived from Borrelia proteins that are expressed at different stages of Lyme disease, and indirectly detecting LD-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-Y) in response to stimulation by the peptides.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: April 20, 2021
    Assignees: QIAGEN Sciences LLC, Biopeptides Corp., Gundersen Lutheran Medical Foundation, Inc.
    Inventors: Steven M. Callister, Jeff Boyle, Misato Miyamasu, Raymond Dattwyler, Paul M. Arnaboldi
  • Patent number: 10961574
    Abstract: The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: March 30, 2021
    Assignee: QIAGEN SCIENCES, LLC
    Inventors: Steven Gordon, Jerzy Olejnik
  • Publication number: 20210078003
    Abstract: A flowcell device for a sequencing by synthesis instrument. The flowcell device has a fluid inlet configured to receive one or more liquid reagents, a fluid outlet configured to pass the one or more liquid reagents, and a channel extending between and fluidly connecting the fluid inlet and the fluid outlet. At least a portion of the channel comprises a reflective structure configured to retain a plurality of sequencing targets thereon. The reflective structure includes at least a metal oxide layer and a film having a first surface and a second surface opposed the first surface. The first surface of the film is disposed on the metal oxide layer and the second surface of the film is configured to receive a plurality of sequencing targets immobilized thereon.
    Type: Application
    Filed: January 25, 2019
    Publication date: March 18, 2021
    Applicants: Qiagen GmbH, Qiagen Sciences, LLC
    Inventors: Sebastian Koeber, Maximilian Focke, Luisa Andruzzi
  • Patent number: 10941438
    Abstract: The present disclosure provides methods and kits for highly multiplex single primer extensions using a MutS protein and Mg2+ at a concentration higher than that in a typical PCR reaction. Also disclosed is the use of such methods and kits in next generation sequencing.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: March 9, 2021
    Assignee: QIAGEN Sciences, LLC
    Inventors: Yexun Wang, Quan Peng
  • Patent number: 10935555
    Abstract: A method of determining suitability of a pregnant woman to be a candidate for induction of labor can include: obtaining a vaginal fluid sample from a pregnant woman; contacting the vaginal fluid sample with a PAMG-1 antibody that binds with PAMG-1; detecting whether the PAMG-1 antibody binds with PAMG-1 in the vaginal fluid sample to form a PAMG-1-antibody complex; and providing the determination of suitability for induction of labor to the pregnant woman. When the PAMG-1-antibody complex forms, the pregnant woman is determined to be in a condition that is not suitable for induction of labor because PAMG-1 is detected in the vaginal sample. When the PAMG-1-antibody complex does not form, the pregnant woman is determined to be in a condition that is suitable to be a candidate for induction of labor because the PAMG-1 is not detected in the vaginal sample.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: March 2, 2021
    Assignee: Qiagen Sciences, LLC
    Inventors: Ruben Salinas, Anthony Ausiello
  • Patent number: 10883099
    Abstract: Provided are methods and compositions for negatively and positively selecting for different size nucleic acid (e.g., DNA or RNA) fragments on borosilicate glass fiber membranes, silica and metal oxide surfaces such that only those fragments falling within a desired size range are obtained.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: January 5, 2021
    Assignee: QIAGEN Sciences, LLC
    Inventors: Vince Moroney, Eddie Adams, Mark N. Brolaski, Ingemar Pedron
  • Patent number: 10844430
    Abstract: The present invention provides methods, compositions, mixtures and kits utilizing 5-Chloro-2-methyl-4-isothiazolin-3-one in sequencing reactions, and in particular, sequencing reactions where deoxynucleoside triphosphates comprising a 3?-O position capped by a disulfide-based 3?-terminator group are used. In one embodiment, the deoxynucleoside triphosphates comprise a 3?-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. In addition, thiol-containing compounds and scavengers of thio-containing compounds are described. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: November 24, 2020
    Assignee: Qiagen Sciences, LLC
    Inventors: Luisa Andruzzi, Jimmy Adediran, Timothy Pelletier, Austin Ricker, Angela DeLucia, Ben McNally, Dona Hevroni, Mong Sano Marma, John Andrew Sheridan
  • Patent number: 10760120
    Abstract: The present disclosure provides methods and kits for performing high multiplex PCR using molecular barcodes. The methods disclosed herein separately extend a set of primers (BC primers) that each comprise a target-specific sequence, a molecular barcode and a universal sequence, and amplify the resulting extension products using another set of primers (LA primers) that each comprise another target-specific sequence and a universal sequence. The methods may further comprise amplification using universal primers (preferably comprising an adapter).
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: September 1, 2020
    Assignee: QIAGEN SCIENCES, LLC
    Inventors: Yexun Wang, Quan Peng